Scientific Reports (Aug 2021)

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

  • Juan Carlos Nieto-González,
  • Laura Trives-Folguera,
  • Alejandra Melgarejo-Ortuño,
  • Aranzazu Ais,
  • Belén Serrano-Benavente,
  • María Sanjurjo,
  • José María Álvaro-Gracia,
  • Indalecio Monteagudo Sáez

DOI
https://doi.org/10.1038/s41598-021-95252-8
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12 months. Persistence of biological therapy was evaluated using Kaplan–Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5 years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6 months, although this was not confirmed at 12 months.